Spruce Biosciences, Inc.
Research Spruce Biosciences, Inc. (SPRB) on Bullrun: market cap USD 109.15M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSPRB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 109.15M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 16.23M
- Free cash flow-USD 22.26M
Valuation Snapshot
latest market cap is USD 109.15M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 38.97M | -USD 33.33M | n/a | -50.83 | USD 48.91M | USD 736.00K | USD 42.52M |
| FY2024 | USD 4.91M | -USD 53.04M | -USD 55.96M | n/a | -96.4 | USD 38.75M | USD 2.77M | USD 28.82M |
| FY2023 | USD 10.09M | -USD 47.92M | -USD 33.28M | n/a | -93 | USD 96.34M | USD 4.61M | USD 76.51M |
| FY2022 | USD 0 | -USD 46.18M | -USD 41.69M | n/a | -147 | USD 24.49M | USD 6.32M | USD 68.49M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | USD 109.15M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 119.51M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.33B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 8.95B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.94B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 589.35B | n/a | n/a | n/a |
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Spruce Biosciences, Inc.'s market cap?
Spruce Biosciences, Inc.'s market capitalization is USD 109.15M.
What does Spruce Biosciences, Inc. do?
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns.